Press Releases

Name: Medicure Inc.
Address: 1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6
Price range: unknown

Medicure Reports Financial Results for Quarter Ended September 30, 2021 Monday, November 22, 2021	Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans Monday, November 22, 2021	Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint Thursday, November 4, 2021
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021 Friday, August 27, 2021	Medicure Announces Grant of Stock Options Friday, July 30, 2021	Medicure Announces Appointment of David Gurvey as Chief Financial Officer Thursday, June 24, 2021
Medicure Reports Financial Results for Quarter Ended March 31, 2021 Monday, May 10, 2021	Medicure 2020 Annual and Q1 2021 Results and Conference Call Date Wednesday, May 5, 2021	Medicure Announces Resignation of Chief Financial Officer and Succession Plan Wednesday, April 28, 2021
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020 Tuesday, April 20, 2021	Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021 Monday, March 29, 2021	Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021 Monday, March 8, 2021
Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021 Monday, February 22, 2021	Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021 Thursday, February 4, 2021	Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Management Wednesday, January 27, 2021
Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency Thursday, January 7, 2021	Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug Thursday, December 17, 2020	Medicure Retains Investor Relations Firm Renmark Financial Communications Inc. Wednesday, December 2, 2020
Medicure Announces Settlement of Patent Infringement Action Wednesday, November 18, 2020	Medicure Reports Financial Results for Quarter Ended September 30, 2020 Wednesday, November 11, 2020	Medicure Q3 2020 Results and Conference Call Dates Thursday, November 5, 2020
Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar Monday, October 5, 2020	Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports Monday, August 24, 2020	Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement Thursday, August 20, 2020
Medicure Reports Financial Results for Quarter Ended June 30, 2020 Tuesday, August 11, 2020	Medicure Q2 2020 Results and Conference Call Dates Wednesday, August 5, 2020	Medicure Announces Normal Course Issuer Bid Monday, June 29, 2020
Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation Monday, June 29, 2020	Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets Thursday, June 25, 2020	Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020 Monday, June 15, 2020
Medicure Reports Financial Results for Quarter Ended March 31, 2020 Tuesday, May 12, 2020	Medicure Q1 2020 results and conference call dates Wednesday, May 6, 2020	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019 Wednesday, April 15, 2020
Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020 Monday, April 13, 2020	Medicure Announces Preliminary Results of Substantial Issuer Bid Friday, December 20, 2019	Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study Tuesday, December 17, 2019
Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI) Thursday, December 12, 2019	Medicure Announces Settlement of Holdback Dispute from Apicore Sale Thursday, December 5, 2019	Medicure Files Patent Infringement Action Thursday, December 5, 2019
Medicure Reports Financial Results for Quarter Ended September 30, 2019 Tuesday, November 26, 2019	Medicure Q3 2019 Results and Conference Call Dates Tuesday, November 19, 2019	Medicure Announces Commencement of Substantial Issuer Bid Wednesday, November 13, 2019
Medicure Announces Intention to Commence Substantial Issuer Bid Monday, November 4, 2019	Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate Tuesday, October 15, 2019	Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force Thursday, October 3, 2019
Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™ Monday, September 30, 2019	Medicure Announces Launch of New and Improved ReDS™ PRO Tuesday, September 17, 2019	Medicure Announces Settlement of Patent Infringement Action Wednesday, August 21, 2019

Newer | Older

Press Releases

Get News Alerts by Email

Medicure Reports Financial Results for Quarter Ended September 30, 2021

Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans

Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint

Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021

Medicure Announces Grant of Stock Options

Medicure Announces Appointment of David Gurvey as Chief Financial Officer

Medicure Reports Financial Results for Quarter Ended March 31, 2021

Medicure 2020 Annual and Q1 2021 Results and Conference Call Date

Medicure Announces Resignation of Chief Financial Officer and Succession Plan

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021

Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Management

Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug

Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

Medicure Announces Settlement of Patent Infringement Action

Medicure Reports Financial Results for Quarter Ended September 30, 2020

Medicure Q3 2020 Results and Conference Call Dates

Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement

Medicure Reports Financial Results for Quarter Ended June 30, 2020

Medicure Q2 2020 Results and Conference Call Dates

Medicure Announces Normal Course Issuer Bid

Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG™ (Pitavastatin) Tablets

Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020

Medicure Reports Financial Results for Quarter Ended March 31, 2020

Medicure Q1 2020 results and conference call dates

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019

Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020

Medicure Announces Preliminary Results of Substantial Issuer Bid

Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Medicure Announces Settlement of Holdback Dispute from Apicore Sale

Medicure Files Patent Infringement Action

Medicure Reports Financial Results for Quarter Ended September 30, 2019

Medicure Q3 2019 Results and Conference Call Dates

Medicure Announces Commencement of Substantial Issuer Bid

Medicure Announces Intention to Commence Substantial Issuer Bid

Medicure Announces SMILE™-HF Study Demonstrates Use of ReDS™ Results in 58% Reduction in Hospital Readmission Rate

Medicure Announces Preferred Pricing Agreement for Zypitamag™ with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force

Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag™

Medicure Announces Launch of New and Improved ReDS™ PRO

Medicure Announces Settlement of Patent Infringement Action

About

Products

News and Media

Investors

Careers

Contact Us